NCT04386304 is a Phase 1 clinical trial of (+)-Epicatechin in Becker Muscular Dystrophy, sponsored by Epirium Bio Inc..

Who is sponsoring NCT04386304?

NCT04386304 is sponsored by Epirium Bio Inc..

What drugs are being tested in NCT04386304?

Interventions in NCT04386304: (+)-Epicatechin.

What condition does NCT04386304 study?

NCT04386304 studies Becker Muscular Dystrophy.

Is NCT04386304 still recruiting?

NCT04386304 is currently completed. Last updated 23 March 2022.

Last reviewed 2022-03-23 · How we verify

NCT04386304

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy

Completed Phase 1 Last updated 23 March 2022

What this trial tests

Phase 1 trial testing (+)-Epicatechin in Becker Muscular Dystrophy in 22 participants. Completed in 1 March 2022.

Timeline

13 July 2020

Primary endpoint
1 March 2022

1 March 2022

Quick facts

Lead sponsor	Epirium Bio Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	13 July 2020
Primary completion	1 March 2022
Estimated completion	1 March 2022
Sites	3 locations across United States

Drugs / interventions tested

(+)-Epicatechin — full drug profile →

Conditions studied

Becker Muscular Dystrophy — all drugs for Becker Muscular Dystrophy →

Sponsor

Epirium Bio Inc.

Who can join

Adults 16 to 59, male only, with Becker Muscular Dystrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, open-label, dose escalation study aimed at evaluating the safety, early efficacy and potential biomarkers of (+)-epicatechin in patients with Becker or Becker-like Muscular Dystrophy (BMD).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?
Kourakis S, Timpani CA, Campelj DG, Hafner P, et al · · 2021 · cited 73× · PMID 33663533 · DOI 10.1186/s13023-021-01758-9
Mitochondria and Reactive Oxygen Species: The Therapeutic Balance of Powers for Duchenne Muscular Dystrophy.
Casati SR, Cervia D, Roux-Biejat P, Moscheni C, et al · · 2024 · cited 17× · PMID 38607013 · DOI 10.3390/cells13070574
An update on Becker muscular dystrophy.
Straub V, Guglieri M. · · 2023 · cited 17× · PMID 37591308 · DOI 10.1097/wco.0000000000001191

Verify or expand the search:

Other recruiting trials for Becker Muscular Dystrophy

Currently open trials in the same condition.

NCT06378203 — Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI] · NA · recruiting
NCT04972604 — CureDuchenne Link®: A Resource for Research · recruiting
NCT01484678 — Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04386304 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Epirium Bio Inc.
Last refreshed: 23 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04386304.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing